Press Release: Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) — MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the admission of the Company’s common shares to the Standard Segment of the Official List’s Main Market.

Among the factors considered by the Company in pursuing the dual listing, Mydecine™ noted that the LSE currently has a limited number of sizable psychedelics-focused biotech companies. Mydecine, as a contributing member to Drug Science UK, the only completely independent, science-led drugs charity, believes the LSE listing will provide UK and European investors with greater, more local exposure to a new high-quality investment choice of a business type not currently available on the Exchange.

Highlights

Mydecine’s appointment of Boustead enables it to commence the LSE listing process and act on its intention for the Company’s common shares to trade on the Main Market in the next few months. In addition to its current listings in Canada, the United States, and Germany, the Company believes that a listing on the LSE makes it well-positioned to bring European investors into the Company’s share register.

The LSE listing is expected to provide all investors access and exposure to:

  • European Investor base in what the Company believes are Psychedelic-friendly countries such as the Netherlands, United Kingdom, Austria, and Portugal, to name a few
  • Support early and late-phase clinical trials
  • Expansion of the Company’s telehealth platform; Mindleap Health
  • Further development of extensive IP portfolio
  • Furthering the development of novel types of psilocybin-based medicine and unique formulations

Josh Bartch, CEO & Chairman of Mydecine Innovations Group, commented, “The Board of Directors has met a number of times deciding the best route and venue for the new listing of the Company’s securities, adding to our focus on shareholder value. We decided the LSE represented the best stock exchange for our investors, shareholders, and the ongoing growth of the Company. Additionally, it provides a great platform to measurably advance our investor reach within the European investor community. A LSE Listing offers a number of opportunities to fast-track further potential listings to exchanges such as NASDAQ or NYSE. Mydecine Innovations Group has a global reach through the Company’s various planned clinical trials, research facilities, partners and scientific advisors, some of which are located directly in the UK.”

About the London Stock Exchange
The London Stock Exchange was founded in 1571 during the reign of Elizabeth I in London, England. The LSE is the 4th largest exchange in the world (based on total market value of its listed companies) and is currently ranked 7th in overall liquidity. As of August 2020, the companies listed on the London Stock Exchange have a combined market capitalisation of ~$4 trillion USD (GBP ~£3,084,232,000,000). Its current premises are situated in Paternoster Square close to St Paul’s Cathedral. It is part of publicly traded London Stock Exchange Group (LSEG).

About Boustead & Company Limited
Boustead & Company Limited is a diversified and comprehensive non-bank financial institution with offices in Los Angeles, New York, San Francisco, London, and Beijing that is rapidly expanding in growth markets throughout the US and Asia. Through its principals and fully licensed subsidiaries, Boustead & Company possesses rich experience and exceptional capabilities in capital markets deal execution and provides best-in-class one-stop financial services to clients. Boustead’s comprehensive financial services platform consists of four operating units: Boustead Securities, LLC a US-based FINRA Broker/Dealer and middle-market investment bank; Sutter Securities Group, Inc., which owns four FINRA-regulated entities: Sutter Securities, Inc., Sutter Securities Clearing, LLC and FlashFunders Funding Portal, LLC, along with Sutter Securities Financial Services, Inc., Sutter Capital Partners, LLC a California Registered Investment Advisor; and Boustead Capital Markets LLP, regulated as an appointed representative in the UK. For more information, please visit www.bousteadco.com.
On behalf of Boustead & Company
Limited

Dan McClory, CEO
[email protected]

About Boustead Capital Markets, LLP
Boustead Capital Markets, LLP, based in London, advises on a wide array of corporate finance assignments across many industries, and is an appointed representative of Thornbridge Investment Management LLP which is authorised and regulated by the FCA. Boustead Capital Markets is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution.
On behalf of Boustead Capital Markets,
LLP

Latest posts